Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Biopharm Stat ; 25(2): 247-59, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25360720

RESUMEN

The concept of quality by design (QbD) as published in ICH-Q8 is currently one of the most recurrent topics in the pharmaceutical literature. This guideline recommends the use of information and prior knowledge gathered during pharmaceutical development studies to provide a scientific rationale for the manufacturing process of a product and provide guarantee of future quality. This poses several challenges from a statistical standpoint and requires a shift in paradigm from traditional statistical practices. First, to provide "assurance of quality" of future lots implies the need to make predictions regarding the quality given past evidence and data. Second, the quality attributes described in the Q8 guidelines are not always a set of unique, independent measurements. In many cases, these criteria are complicated longitudinal data with successive acceptance criteria over a defined period of time. A common example is a dissolution profile for a modified or extended-release solid dosage form that must fall within acceptance limits at several time points. A Bayesian approach for longitudinal data obtained in various conditions of a design of experiment is provided to elegantly address the ICH-Q8 recommendation to provide assurance of quality and derive a scientifically sound design space.


Asunto(s)
Biofarmacia/estadística & datos numéricos , Modelos Estadísticos , Tecnología Farmacéutica/estadística & datos numéricos , Teorema de Bayes , Biofarmacia/normas , Química Farmacéutica , Interpretación Estadística de Datos , Preparaciones de Acción Retardada , Guías como Asunto , Cinética , Control de Calidad , Solubilidad , Comprimidos , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas , Factores de Tiempo
2.
J Biopharm Stat ; 25(2): 260-8, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25357001

RESUMEN

Since the adoption of the ICH Q8 document concerning the development of pharmaceutical processes following a quality by design (QbD) approach, there have been many discussions on the opportunity for analytical procedure developments to follow a similar approach. While development and optimization of analytical procedure following QbD principles have been largely discussed and described, the place of analytical procedure validation in this framework has not been clarified. This article aims at showing that analytical procedure validation is fully integrated into the QbD paradigm and is an essential step in developing analytical procedures that are effectively fit for purpose. Adequate statistical methodologies have also their role to play: such as design of experiments, statistical modeling, and probabilistic statements. The outcome of analytical procedure validation is also an analytical procedure design space, and from it, control strategy can be set.


Asunto(s)
Biofarmacia/estadística & datos numéricos , Modelos Estadísticos , Tecnología Farmacéutica/estadística & datos numéricos , Teorema de Bayes , Biofarmacia/normas , Química Farmacéutica , Interpretación Estadística de Datos , Guías como Asunto , Probabilidad , Control de Calidad , Reproducibilidad de los Resultados , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA